Altimmune Total Assets vs Net Debt Analysis

ALT Stock  USD 8.25  0.07  0.86%   
Altimmune financial indicator trend analysis is way more than just evaluating Altimmune prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Altimmune is a good investment. Please check the relationship between Altimmune Total Assets and its Net Debt accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Altimmune. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For more information on how to buy Altimmune Stock please use our How to Invest in Altimmune guide.

Total Assets vs Net Debt

Total Assets vs Net Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Altimmune Total Assets account and Net Debt. At this time, the significance of the direction appears to have pay attention.
The correlation between Altimmune's Total Assets and Net Debt is -0.94. Overlapping area represents the amount of variation of Total Assets that can explain the historical movement of Net Debt in the same time period over historical financial statements of Altimmune, assuming nothing else is changed. The correlation between historical values of Altimmune's Total Assets and Net Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Assets of Altimmune are associated (or correlated) with its Net Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Debt has no effect on the direction of Total Assets i.e., Altimmune's Total Assets and Net Debt go up and down completely randomly.

Correlation Coefficient

-0.94
Relationship DirectionNegative 
Relationship StrengthSignificant

Total Assets

Total assets refers to the total amount of Altimmune assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Altimmune books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.
Most indicators from Altimmune's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Altimmune current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Altimmune. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For more information on how to buy Altimmune Stock please use our How to Invest in Altimmune guide.At this time, Altimmune's Tax Provision is comparatively stable compared to the past year. Sales General And Administrative To Revenue is likely to gain to 44.70 in 2024, despite the fact that Enterprise Value Over EBITDA is likely to grow to (5.02).
 2021 2022 2023 2024 (projected)
Research Development74.5M70.5M65.8M69.1M
Depreciation And Amortization551.3K500K477K435.7K

Altimmune fundamental ratios Correlations

0.40.430.85-0.94-0.420.460.940.980.080.780.370.650.450.990.20.19-0.120.02-0.25-0.240.050.010.470.180.81
0.41.0-0.14-0.440.3-0.010.430.450.39-0.12-0.08-0.261.00.420.35-0.11-0.1-0.290.24-0.12-0.22-0.190.93-0.290.37
0.431.0-0.11-0.480.270.030.470.480.41-0.09-0.03-0.221.00.450.36-0.06-0.12-0.310.25-0.13-0.23-0.20.94-0.30.36
0.85-0.14-0.11-0.75-0.640.490.760.8-0.150.910.420.85-0.090.830.010.26-0.050.19-0.42-0.180.20.1-0.040.350.68
-0.94-0.44-0.48-0.750.48-0.49-1.0-0.95-0.25-0.75-0.55-0.64-0.48-0.94-0.35-0.420.250.250.140.370.120.1-0.55-0.04-0.62
-0.420.30.27-0.640.48-0.67-0.5-0.5-0.3-0.84-0.15-0.940.26-0.45-0.47-0.130.430.290.030.550.310.330.280.07-0.31
0.46-0.010.030.49-0.49-0.670.490.490.260.630.160.640.030.470.40.18-0.27-0.220.18-0.32-0.22-0.150.15-0.090.33
0.940.430.470.76-1.0-0.50.490.960.250.760.540.660.480.940.340.41-0.26-0.25-0.14-0.38-0.12-0.120.530.040.63
0.980.450.480.8-0.95-0.50.490.960.220.780.340.680.490.980.340.17-0.26-0.16-0.15-0.38-0.1-0.120.490.080.82
0.080.390.41-0.15-0.25-0.30.260.250.22-0.02-0.010.130.40.140.950.06-0.42-0.650.51-0.45-0.61-0.620.31-0.36-0.01
0.78-0.12-0.090.91-0.75-0.840.630.760.78-0.020.330.95-0.070.780.180.22-0.20.0-0.3-0.340.02-0.07-0.030.080.6
0.37-0.08-0.030.42-0.55-0.150.160.540.34-0.010.330.27-0.040.34-0.050.96-0.08-0.18-0.15-0.090.050.170.20.16-0.15
0.65-0.26-0.220.85-0.64-0.940.640.660.680.130.950.27-0.210.660.310.18-0.31-0.11-0.2-0.44-0.12-0.19-0.210.10.5
0.451.01.0-0.09-0.480.260.030.480.490.4-0.07-0.04-0.210.460.35-0.08-0.14-0.290.24-0.15-0.24-0.160.94-0.260.39
0.990.420.450.83-0.94-0.450.470.940.980.140.780.340.660.460.260.18-0.09-0.02-0.2-0.220.07-0.10.470.130.81
0.20.350.360.01-0.35-0.470.40.340.340.950.18-0.050.310.350.260.01-0.42-0.60.43-0.48-0.58-0.630.26-0.360.12
0.19-0.11-0.060.26-0.42-0.130.180.410.170.060.220.960.18-0.080.180.01-0.05-0.240.02-0.040.020.070.170.09-0.35
-0.12-0.1-0.12-0.050.250.43-0.27-0.26-0.26-0.42-0.2-0.08-0.31-0.14-0.09-0.42-0.050.7-0.240.970.93-0.03-0.050.04-0.13
0.02-0.29-0.310.190.250.29-0.22-0.25-0.16-0.650.0-0.18-0.11-0.29-0.02-0.6-0.240.7-0.380.740.740.49-0.270.510.09
-0.250.240.25-0.420.140.030.18-0.14-0.150.51-0.3-0.15-0.20.24-0.20.430.02-0.24-0.38-0.13-0.38-0.480.14-0.01-0.23
-0.24-0.12-0.13-0.180.370.55-0.32-0.38-0.38-0.45-0.34-0.09-0.44-0.15-0.22-0.48-0.040.970.74-0.130.880.08-0.060.16-0.25
0.05-0.22-0.230.20.120.31-0.22-0.12-0.1-0.610.020.05-0.12-0.240.07-0.580.020.930.74-0.380.880.07-0.140.180.05
0.01-0.19-0.20.10.10.33-0.15-0.12-0.12-0.62-0.070.17-0.19-0.16-0.1-0.630.07-0.030.49-0.480.080.07-0.050.48-0.04
0.470.930.94-0.04-0.550.280.150.530.490.31-0.030.2-0.210.940.470.260.17-0.05-0.270.14-0.06-0.14-0.05-0.30.28
0.18-0.29-0.30.35-0.040.07-0.090.040.08-0.360.080.160.1-0.260.13-0.360.090.040.51-0.010.160.180.48-0.30.15
0.810.370.360.68-0.62-0.310.330.630.82-0.010.6-0.150.50.390.810.12-0.35-0.130.09-0.23-0.250.05-0.040.280.15
Click cells to compare fundamentals

Altimmune Account Relationship Matchups

Altimmune fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets54.1M245.1M218.9M206.9M210.6M221.2M
Other Current Liab3.6M11.0M6.1M10.6M9.6M17.0M
Total Current Liabilities3.9M12.0M18.3M17.1M12.1M21.2M
Total Stockholder Equity45.5M225.9M199.1M185.3M194.1M203.8M
Net Debt(7.2M)(114.1M)(188.8M)(110.0M)(134.4M)(127.7M)
Retained Earnings(137.4M)(186.4M)(293.2M)(377.9M)(466.3M)(443.0M)
Accounts Payable18.2K612.3K2.0M4.8M2.1M1.5M
Cash9.0M115.9M190.3M111.1M135.1M141.9M
Cash And Short Term Investments37.2M215.9M190.3M184.9M197.8M207.7M
Common Stock Total Equity876.01.5K3.7K4.1K4.7K3.9K
Common Stock Shares Outstanding13.1M25.6M41.3M46.9M53.2M55.9M
Liabilities And Stockholders Equity54.1M245.1M218.9M206.9M210.6M221.2M
Other Current Assets504.4M2.0B13.4B5.4M7.0M6.6M
Other Stockholder Equity187.9M417.3M497.3M568.4M665.4M698.7M
Total Liab8.5M19.2M19.7M21.6M16.5M27.3M
Total Current Assets39.4M230.3M204.1M192.8M209.6M220.1M
Common Stock1.5K3.7K4.1K5K7K4.2K
Other Assets128.5K977.2K73.8K19K1.00.95
Non Current Liabilities Total4.6M7.2M1.5M4.6M4.4M4.7M
Short Term Debt259.4K356.7K411.5K452K496K471.2K
Short Long Term Debt Total2.1M2.2M1.9M1.1M671K637.5K
Property Plant And Equipment Net1.8M2.0M1.4M1.1M1.0M1.5M
Non Current Assets Total14.7M14.9M14.7M14.1M1.0M963.3K
Non Currrent Assets Other128.5K73.4K872.0K615K100.0K95.0K
Net Receivables1.7M12.4M5.8M2.5M4.9M5.0M
Property Plant And Equipment Gross1.8M2.0M1.4M2.6M2.6M1.6M
Accumulated Other Comprehensive Income(5.0M)(5.0M)(5.0M)(5.2M)(5.0M)(4.8M)
Intangible Assets12.7M12.8M12.4M12.4M14.3M11.8M
Net Tangible Assets32.8M213.1M186.7M172.9M198.8M208.7M
Long Term Debt1.9M1.9M1.8M1.5M1.7M1.5M
Retained Earnings Total Equity(116.9M)(137.4M)(186.4M)(293.2M)(337.1M)(354.0M)
Capital Surpluse170.2M187.9M417.3M497.3M571.9M600.5M
Property Plant Equipment1.1M1.1M1.4M1.7M1.9M2.0M
Long Term Debt Total1.9M1.9M1.8M1.5M1.7M2.0M
Non Current Liabilities Other2.8M5.4M1.5M3.9M4.2M4.4M
Other Liab3.1M7.2M330.5K3.9M4.5M3.3M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Altimmune Stock Analysis

When running Altimmune's price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.